JAJoão Pedro Alves-Lopes

João Pedro Alves-Lopes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


João Pedro Alves-Lopes has a total of 59 co-authors. Here are the top co-authors by number of shared publications:

  • Jan-Bernd Stukenborg

    NORDFERTIL Research Lab Stockholm, Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital, Solna, Sweden

    6 shared publications
  • Kirsi Jahnukainen

    Karolinska Institutet Childhood Cancer Research Unit, Department of Women’s and Children’s Health Stockholm

    3 shared publications
  • M. Azim Surani

    Gurdon Institute, University of Cambridge, Cambridge, UK

    3 shared publications
  • Olle Söder

    Department of Women's and Children's Health, NORDFERTIL Research Lab Stockholm, Pediatric Endocrinology Unit; Q2:08; Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

    3 shared publications
  • Leah Nic Aodha

    Karolinska Institutet Childhood Cancer Research Unit, Department of Women’s and Children’s Health Stockholm

    2 shared publications
  • Navin B. Ramakrishna

    Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR) 1 , 60 Biopolis Street, Genome, Singapore 138672

    2 shared publications

Latest Publications

  • Open Access

    PFOS disrupts the development of early germline and surrounding embryonic soma at environmentally relevant exposure levels

    by Silvia Pérez Casasús, Leah Nic Aodha, Tiago Macedo, Sonia Youhanna, Francesca Paola Luongo, Laura Governini, Alice Luddi, Paola Piomboni, Nikolas Herold, Kirsi Jahnukainen, et al.

    STUDY QUESTION: Can an embryoid body model of germ cell specification predict the impact of per- and polyfluoroalkyl substances (PFAS) on early embryonic and germline development at exposure levels relevant to human populations? SUMMARY ANSWER: Perfluorooctanesulfonic acid (PFOS) impairs early germline specification and surrounding embryonic somatic development in the embryoid body system at exposure levels detected in the serum of pregnant women. WHAT IS KNOWN ALREADY: PFAS are highly stable and persistent synthetic chemicals used in industrial processes and consumer products widely detected in humans. Although mounting evidence indicates that chronic PFAS exposure and bioaccumulation can adversely affect human health, their impact on early embryonic and germline development remains largely unknown. STUDY DESIGN, SIZE, DURATION: We used a stem cell-based human embryoid body model for early germ cell specification to assess the effects of commonly environmentally found PFAS, perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and perfluorohexanesulfonic acid (PFHxS), on human germ cell specification and early embryonic somatic development. PFAS exposure levels were chosen to reflect serum concentrations measured in pregnant women in Sweden, with the 1× nominal concentration defined as 7 nM for PFOS and 4 nM for both PFOA and PFHxS. For each compound control, 1×, 5×, 10×, 25×, or 100× exposures were compared. Four experimental replicates were carried out for each tested compound. PARTICIPANTS/MATERIALS, SETTING, METHODS: Human induced pluripotent stem cells (hiPSCs) were exposed to PFOS, PFOA, and PFHxS to assess their effects on cell growth, embryoid body development, and germ cell specification. hiPSC expansion and embryoid body development were monitored by phase-contrast microscopy. Following differentiation, germ cells were quantified by fluorescence-activated cell sorting (FACS) after embryoid body dissociation and staining for the early human germ cell surface markers tissue-nonspecific alkaline phosphatase (TNAP) and podoplanin (PDPN). Bulk RNA sequencing was performed to evaluate the effects of PFAS exposure on the transcriptomic landscape of the in vitro-derived germ cells. MAIN RESULTS AND THE ROLE OF CHANCE: When exposing the embryoid bodies to PFAS concentrations resembling the levels measured in the bloodstream of pregnant women, we find that PFOS impaired embryoid body development in a concentration-dependent manner, with effects already observed at the levels detected in that population group. On the other hand, PFOA caused a slight, non-significant downward trend in embryoid body size, while PFHxS induced weaker and non-monotonic effects. Upon PFOS exposure, germ cells were still specified but exhibited marked transcriptomic alterations, characterized by suppression of developmental and signalling pathways and enrichment of RNA-processing and ribosome biogenesis. In contrast, no significantly differentially expressed genes were detected in their precursors following PFOS exposure. LARGE SCALE DATA: N/A LIMITATIONS, REASONS FOR CAUTION: Although the embryoid body model closely captures the posterior region of the gastrulating post-implantation embryo, it does not fully recapitulate the entire embryo and its implantation environment. WIDER IMPLICATIONS OF THE FINDINGS: Collectively, our results identify PFOS as a potent disruptor of embryonic and germline development and establish the embryoid body model for early germ cell specification as a robust and sensitive candidate new approach methodology (NAM) for evaluating developmental and reproductive toxicity (DART) at relevant exposure levels for human populations. FUNDING: L.N.A. acknowledges support from the Marie Skłodowska-Curie Actions Individual Fellowship (101278886: GERMFIT) from the European Commission. T.M. acknowledges support from Sällskapet Barnavård (2026-012). K.J. acknowledges support from the Foundation for Pediatric Research, the Finnish Cancer Society, the Swedish Childhood Cancer Foundation (KP2020-0012), and the Birgitta and Carl-Axel Rydbeck’s Research Grant for Paediatric Research (2020-00335, 2021-00079, and 2023-00380). Y.Z. acknowledges support from National Natural Science Foundation of China (Youth Program; grant number: 82505173), and the National Academic Infrastructure for Supercomputing in Sweden (NAISS), partially funded by the Swedish Research Council through grant agreement no. 2022-06725. P.D. acknowledges support from Swedish Research Council FORMAS (2024-01415) and Karolinska Institutet consolidator grant. V.M.L. acknowledges support from the ERC Consolidator Grant 3DMASH (101170408), the European Union's Horizon Europe program NEMESIS (101137405), the Swedish Research Council (2021-02801, 2023-03015 and 2024-03401), the Novo Nordisk Foundation (NNF23OC0085944 and NNF23OC0084420) and the Robert Bosch Foundation, Stuttgart. J.P.A.-L was supported by a Starting Grant in Medicine and Health (2022-01467) from the Swedish Research Council and Birgitta and Carl-Axel Rydbeck Research Grant for Paediatric Research (2024-00208). DISCLOSURES: V.M.L. is CEO and shareholder of HepaPredict AB, as well as co-founder and shareholder of Shanghai Hepo Biotechnology Ltd. All other authors declare no conflicts of interest.

  • Open Access

    Human iPSCs derived from cryopreserved testicular somatic cells enable germline regeneration in childhood cancer survivors

    by Tiago Macedo, Claudia De Guidi, Leah Nic Aodha, Nageswara Rao Boggavarapu, Maja Piechocka, Xuan Ye, Francesca Mastropasqua, Victoria Keros, Ulrika Norén Nyström, Per Frisk, et al.

    STUDY QUESTION: Can cryopreserved primary testicular somatic cells from childhood cancer survivors with severely decreased fertility potential be reprogrammed into human induced pluripotent stem cells (hiPSCs) competent for efficient specification into early human germ cells? SUMMARY ANSWER: Primary testicular somatic cells from cryopreserved testicular samples with severely compromised spermatogonial pools can be reprogrammed into hiPSCs using a non-genome-integrating, feeder-free approach and subsequently differentiated into human primordial germ cell-like cells (hPGCLCs) with high efficiency. WHAT IS KNOWN ALREADY: Infertility is one of the most concerning long-term side effects of cancer therapy in prepubertal boys, yet it remains largely unaddressed. Worldwide, biobanks storing cryopreserved immature testicular tissue are expanding to support the development of fertility preservation strategies, including future tissue and cell transplantation approaches. However, whether these samples can also serve as starting material to generate hiPSCs and subsequently differentiated into in vitro-derived germ cells remains largely unexplored. Currently, there are established protocols for non-genome-integrating reprogramming of somatic cells into hiPSCs and for hPGCLC specification that could be applied to cryopreserved testicular tissue, with special relevance for patient samples severely depleted of germ cells. STUDY DESIGN, SIZE, DURATION: Two biological replicates of cryopreserved prepubertal testicular tissue were used to obtain primary somatic cells, which were reprogrammed into hiPSCs and subsequently differentiated into hPGCLCs. This experimental pipeline had a duration of approximately four months. PARTICIPANTS/MATERIALS, SETTING, METHODS: Cryopreserved testicular tissue samples were obtained from two prepubertal cancer patients (6.2 and 6.3 years old) with depleted spermatogonial pools (spermatogonia count per round tubular cross-section of 0.04 and 0.02, and age-standardized Z-scores of − 17.62 and −20.48). These samples were subsequently used to derive primary testicular somatic cell cultures, which were then reprogrammed into hiPSCs using a clinically compatible, non-genome-integrating mRNA-based method under feeder-free conditions. The resulting hiPSC lines were validated and subsequently differentiated into hPGCLCs using two different specification protocols. The transcriptomic profiles of the hiPSCs and their derived hPGCLCs were verified using bulk RNA sequencing. MAIN RESULTS AND THE ROLE OF CHANCE: Here, we present the first successful generation of hiPSCs from cryopreserved testicular somatic cells of childhood cancer patients with a severely depleted germ cell pool. We accomplished this using a non-genome-integrating mRNA-based reprogramming approach. We further demonstrated the specification of hPGCLCs from these patient-derived hiPSCs, effectively regenerating their germline. This provides proof-of-concept for a stem cell-based fertility regeneration strategy in childhood cancer survivors with non-functional or absent germ cells. LARGE SCALE DATA: N/A LIMITATIONS, REASONS FOR CAUTION: This proof-of-concept study was limited by a small sample size, due to the restricted access to cryopreserved human prepubertal testicular tissues. Although multiple hiPSC clones were generated per individual, only one clone per patient was used for downstream analyses, precluding systematic assessment of intra-individual clonal variability, which remains an important aspect for future studies. While G-banding karyotyping was sufficient to validate genomic integrity in this proof‑of‑concept study, more comprehensive genetic and epigenetic analyses should be prioritized in future hiPSC and hPGCLC validation before any clinical application is considered. WIDER IMPLICATIONS OF THE FINDINGS: Childhood cancer patient-derived hiPSCs represent a powerful platform to investigate and address a broad range of long-term, cancer therapy-related complications. These hiPSCs and their derived germ cells may be used not only to develop in vitro gametogenesis protocols, but also to investigate mechanisms of cancer therapy toxicity and resistance among different patients, to identify early biomarkers of adverse outcomes, and to screen for germ cell protective agents. Importantly, cancer patient-specific hiPSCs have applications that extend well beyond germline, enabling regenerative strategies targeting other treatment-related sequelae through the generation of relevant somatic cell types. STUDY FUNDING/COMPETING INTEREST(S): T.M. was supported by the Erasmus+ program, as part of the projects WORK4ALL 2023 and WORK4ALL 2024 (2023-1-PT01-KA131-HED-000121324 and 2024-1-PT01-KA131-HED-000214636). J.P.A.-L. was supported by a Starting Grant in Medicine and Health (2022-01467) from the Swedish Research Council and Birgitta, the Carl-Axel Rydbeck Research Grant 2024 (2024- 00208), and the Scientific Fund Willy Gepts. Y.B. was supported by the Scientific Fund Willy Gepts. K.J. was supported by the Foundation for Pediatric Research, the Finnish Cancer Society, the Swedish Childhood Cancer Foundation (KP2020-0012), and the Birgitta and Carl-Axel Rydbeck’s Research Grant for Paediatric Research (2020-00335, 2021-00079, and 2023-00380). J.-B.S. was supported by the Swedish Childhood Cancer Fund (PR2019-0123; PR2022-0115; TJ2020-0023), and the Swedish Research Council (2018-03094; 2021-02107). All authors declare no conflict of interest.


  • Open Access

    The road to restore male fertility using in vitro -derived germ cells

    by Tiago Macedo, João Pedro Alves-Lopes

    BACKGROUND: Human-induced pluripotent stem cells (hiPSCs) offer immense potential in reproductive medicine, particularly for males who lack germ cells and cannot achieve biological parenthood through conventional ARTs. Early efforts to derive human germ cells from stem cells were hindered by low efficiency, subpar characterization, and the lack of standardized differentiation approaches. However, recent advancements have led to the development of defined protocols that mimic early embryonic development and allow the specification of transcriptomically and epigenetically validated human primordial germ cell-like cells (hPGCLCs). Current research focuses on maturing hPGCLCs in vitro, particularly within 3D culture systems that resemble their physiological microenvironment, with the aim of producing transplantable hiPSC-derived spermatogonial stem cells (SSCs) or differentiating them to sperm. At the same time, researchers are also testing whether hiPSCs generated from infertile patients can resume germline differentiation. OBJECTIVE AND RATIONALE: This narrative review aimed to summarize the key efforts and remaining challenges in differentiating male germ cells from human pluripotent stem cells (hPSCs), with a particular focus on defined and validated protocols for hPGCLC specification. In parallel, we addressed key safety and ethical considerations that must be accounted for the development of clinical applications. A deeper understanding of the approaching therapeutic use of hiPSCs in reproductive medicine is essential for developing novel regenerative fertility strategies. SEARCH METHODS: PubMed, Scopus, and Web of Science were searched for studies attempting germ cell differentiation from hPSCs using relevant keywords (‘stem cells’, ‘human pluripotent stem cells’, ‘human embryonic stem cells’, ‘human induced pluripotent stem cells’, ‘somatic cell reprogramming’, ‘infertility’, ‘germline’, ‘spermatogenesis’, ‘germ cells’, and ‘primordial germ cells’). No time period restriction was established. Studies with an exclusive focus on female germline differentiation were excluded. To maintain a human-focused perspective, only key animal studies are presented. OUTCOMES: The literature reveals a clear segregation among protocols for deriving germ cells from hPSCs, particularly between earlier studies lacking standardized differentiation conditions and characterization, and the most recent, defined protocols having transcriptomic and epigenetic validation against in vivo hPGCs. Moreover, during the last decade, the field has seen remarkable progress, with multiple efforts aimed at maturing hPGCLCs, closely recapitulating late male embryonic germline development. Additionally, hiPSCs derived from male patients at risk of infertility, particularly those without underlying genetic syndromes, generally retain the capacity for early germline commitment. While attempts at maturating patient germ cells beyond the hPGCLC state remain limited, the rapid pace of discovery and refinement in recent years suggests that further breakthroughs, including clinically applicable fertility restoration strategies, are likely to be achieved in the near future. WIDER IMPLICATIONS: The ability to generate hiPSCs from infertile patients and to specify them into hPGCLCs supports the feasibility of obtaining hiPSC-derived SSCs for future therapeutic use. These advances raise important ethical, regulatory, and societal questions that must be actively discussed among researchers, clinicians, policymakers, and the general public to ensure responsible and equitable access to these technologies. REGISTRATION NUMBER: N/A.


  • Open Access

    Emerging principles and models of human primordial germ cell development

    by Navin B. Ramakrishna, João Pedro Alves-Lopes, Wolfram H. Gruhn

    In humans, primordial germ cells (hPGCs) are the earliest precursors committed to forming sperm or egg. During the first trimester of embryonic development, hPGCs undergo extensive epigenetic reprogramming and are subject to fitness selection, laying the foundation for future gametogenesis and normal embryonic development. During these processes, hPGCs interact with dynamic microenvironments that remain incompletely understood. Recent advances in transcriptomic and epigenetic profiling have revealed signalling cues and regulatory mechanisms governing hPGC development in human embryos, complemented by insights from non-human primate models. In parallel, pluripotent stem cell-based systems that model hPGC differentiation have emerged in the past decade as valuable platforms for mechanistic studies and form the basis of ongoing efforts to establish human in vitro gametogenesis. In this Review, we discuss the microenvironmental and epigenetic changes accompanying hPGC specification, migration and gonadal development up to week 10 of embryogenesis. Building on these insights, we examine current model systems for recapitulating hPGC development, and highlight the mechanistic understandings they have enabled.


  • Human primordial germ cell-like cells specified from resetting precursors develop in human hindgut organoids

    by João Pedro Alves-Lopes, Frederick C. K. Wong, M. Azim Surani

    Human primordial germ cells (hPGCs), the precursors of eggs and sperm, start their complex development shortly after specification and during their migration to the primitive gonads. Here, we describe protocols for specifying hPGC-like cells (hPGCLCs) from resetting precursors and progressing them with the support of human hindgut organoids. Resetting hPGCLCs (rhPGCLCs) are specified from human embryonic stem cells (hESCs) transitioning from the primed into the naive state of pluripotency. Hindgut organoids are also derived from hESCs after a sequential differentiation into a posterior endoderm/hindgut fate. Both rhPGCLCs and hindgut organoids are combined and co-cultured for 25 d. The entire procedure takes ~1.5 months and can be successfully implemented by a doctoral or graduate student with basic skills and experience in hESC cultures. The co-culture system supports the progression of rhPGCLCs at a developmental timing analogous to that observed in vivo. Compared with previously developed hPGCLC progression protocols, which depend on co-cultures with mouse embryonic gonadal tissue, our co-culture system represents a developmentally relevant model closer to the environment that hPGCs first encounter after specification. Together with the potential for investigations of events during hPGC specification and early development, these protocols provide a practical approach to designing efficient models for in vitro gametogenesis. Notably, the rhPGCLC-hindgut co-culture system can also be adapted to study failings in hPGC migration, which are associated with the etiology of some forms of infertility and germ cell tumors.


  • Epigenetic resetting in the human germ line entails histone modification remodeling

    by Wolfram H. Gruhn, Walfred W.C. Tang, Sabine Dietmann, João P. Alves-Lopes, Christopher A. Penfold, Frederick C. K. Wong, Navin B. Ramakrishna, M. Azim Surani

    Epigenetic resetting in the mammalian germ line entails acute DNA demethylation, which lays the foundation for gametogenesis, totipotency, and embryonic development. We characterize the epigenome of hypomethylated human primordial germ cells (hPGCs) to reveal mechanisms preventing the widespread derepression of genes and transposable elements (TEs). Along with the loss of DNA methylation, we show that hPGCs exhibit a profound reduction of repressive histone modifications resulting in diminished heterochromatic signatures at most genes and TEs and the acquisition of a neutral or paused epigenetic state without transcriptional activation. Efficient maintenance of a heterochromatic state is limited to a subset of genomic loci, such as evolutionarily young TEs and some developmental genes, which require H3K9me3 and H3K27me3, respectively, for efficient transcriptional repression. Accordingly, transcriptional repression in hPGCs presents an exemplary balanced system relying on local maintenance of heterochromatic features and a lack of inductive cues.


  • Open Access

    Specification of human germ cell fate with enhanced progression capability supported by hindgut organoids

    by João Pedro Alves-Lopes, Frederick C.K. Wong, Walfred W.C. Tang, Wolfram H. Gruhn, Navin B. Ramakrishna, Geraldine M. Jowett, Kirsi Jahnukainen, M. Azim Surani


  • Top Cited Papers
    Open Access

    Spermatogonial quantity in human prepubertal testicular tissue collected for fertility preservation prior to potentially sterilizing therapy

    by J -B Stukenborg, J P Alves-Lopes, M Kurek, H Albalushi, A Reda, V Keros, V Töhönen, R Bjarnason, P Romerius, M Sundin, et al.

    Does chemotherapy exposure (with or without alkylating agents) or primary diagnosis affect spermatogonial quantity in human prepubertal testicular tissue? Spermatogonial quantity is significantly reduced in testes of prepubertal boys treated with alkylating agent therapies or with hydroxyurea for sickle cell disease. Cryopreservation of spermatogonial stem cells, followed by transplantation into the testis after treatment, is a proposed clinical option for fertility restoration in children. The key clinical consideration behind this approach is a sufficient quantity of healthy cryopreserved spermatogonia. However, since most boys with malignancies start therapy with agents that are not potentially sterilizing, they will have already received some chemotherapy before testicular tissue cryopreservation is considered. We examined histological sections of prepubertal testicular tissue to elucidate whether chemotherapy exposure or primary diagnosis affects spermatogonial quantity. Quantity of spermatogonia per transverse tubular cross-section (S/T) was assessed in relation to treatment characteristics and normative reference values in histological sections of paraffin embedded testicular tissue samples collected from 32 consecutive boy patients (aged 6.3 ± 3.8 [mean ± SD] years) between 2014 and 2017, as part of the NORDFERTIL study, and in 14 control samples (from boys aged 5.6 ± 5.0 [mean ± SD] years) from an internal biobank. Prepubertal boys in Sweden, Finland and Iceland who were facing treatments associated with a very high risk of infertility, were offered the experimental procedure of testicular cryopreservation. Exclusion criteria were testicular volumes >10 ml and high bleeding or infection risk. There were 18 patients with a diagnosis of malignancy and 14 patients a non-malignant diagnosis. While 20 patients had the testicular biopsy performed 1–45 days after chemotherapy, 12 patients had not received any chemotherapy. In addition, 14 testicular tissue samples of patients with no reported testicular pathology, obtained from the internal biobank of the Department of Pathology at Karolinska University Hospital, were included as control samples in addition to reference values obtained from a recently published meta-analysis. The quantity of spermatogonia was assessed by both morphological and immunohistochemical analysis. The main finding was a significant reduction in spermatogonial cell counts in boys treated with alkylating agents or with hydroxyurea for sickle cell disease. The mean S/T values in boys exposed to alkylating agents (0.2 ± 0.3, n = 6) or in boys with sickle cell disease and exposed to hydroxyurea (0.3 ± 0.6, n = 6) were significantly lower (P = 0.003 and P = 0.008, respectively) than in a group exposed to non-alkylating agents or in biobank control samples (1.7 ± 1.0, n = 8 and 4.1 ± 4.6, n = 14, respectively). The mean S/T values of the testicular tissue samples included in the biobank control group and the patient group exposed to non-alkylating agents were within recently published normative reference values. Normal testicular tissue samples included in this study were obtained from the internal biobank of Karolinska University Hospital. Samples were considered normal and included in the study if no testicular pathology was reported in the analysed samples. However, detailed information regarding previous medical treatments and testicular volumes of patients included in this biobank were not available. This study summarizes, for the first time, spermatogonial quantity in a prepubertal patient cohort just before and after potentially sterilizing treatments. Boys facing cancer and cytotoxic therapies are regarded as the major group who will benefit from novel fertility preservation techniques. There are no previous reports correlating spermatogonial quantity to cumulative exposure to alkylating agents and anthracyclines (non-alkylating agents) and no information about the timing of cytotoxic exposures among this particular patient cohort. For prepubertal boys in whom fertility preservation is indicated, testicular tissue should be obtained before initiation of chemotherapy with alkylating agents, whilst for those with sickle cell disease and treated with hydroxyurea, this approach to fertility preservation may not be feasible. This study was supported by grants from The Swedish Childhood Cancer Foundation (PR2016-0124; TJ2016-0093; PR2015-0073, TJ2015-0046) (J.-B.S. and K.J.), the Jane and Dan Olssons Foundation (2016-33) (J.-B.S.), the Finnish Cancer Society (K.J.), the Foundation for Paediatric Research (J.-B.S.), Kronprinsessan Lovisas Förening För Barnasjukvård/ Stiftelsen Axel Tielmans Minnesfond, Samariten Foundation (J.-B.S.), the Väre Foundation for Paediatric Cancer Research (K.J.) and the Swedish Research Council (2012-6352) (O.S.). R.T.M. was supported by a Wellcome Trust Fellowship (09822). J.P.A.-L. and M.K. were supported by the ITN Marie Curie program ‘Growsperm’ (EU-FP7-PEOPLE-2013-ITN 603568). The authors declare no conflicts of interest. N/A.


  • Use of a three-layer gradient system of cells for rat testicular organoid generation

    by João Pedro Alves-Lopes, Olle Söder, Jan-Bernd Stukenborg

    We have recently developed a 3D culture system that allows the reorganization of rat primary testicular cells into organoids with a functional blood–testis barrier, as well as the establishment and maintenance of germ cells. The innovative aspect of our model, the three-layer gradient system (3-LGS), comprises cells combined with Matrigel placed between two layers of Matrigel without cells, which creates a gradient of cells and allows the reorganization of testicular cells into organized structures after 5–7 d in culture. This reorganization is not observed when testicular cells are suspended in only one layer of Matrigel, the methodology used in the majority of the protocols for generating organoids. The model can be applied to follow and quantify cell migration during testicular organoid formation, and to explore the role of growth factors and the toxic effects of drugs and environmental contaminants on germ cell maintenance and blood–testis barrier integrity. The 3-LGS is a robust and reproducible method that requires a small volume of Matrigel and a low number of cells (16 μl and 132,000 cells, respectively), enabling and facilitating high-throughput analysis of germ-to-somatic cell associations in vitro.


  • Open Access

    Testicular organoids: a new model to study the testicular microenvironment in vitro?

    by João Pedro Alves-Lopes, Jan-Bernd Stukenborg

    In recent decades, a broad range of strategies have been applied to model the testicular microenvironment in vitro. These models have been utilized to study testicular physiology and development. However, a system that allows investigations into testicular organogenesis and its impact in the spermatogonial stem-cell (SSC) niche in vitro has not been developed yet. Recently, the creation of tissue-specific organ-like structures called organoids has resurged, helping researchers to answer scientific questions that previous in vitro models could not help to elucidate. So far, a small number of publications have concerned the generation of testicular organoids and their application in the field of reproductive medicine and biology. Here, we aim to elucidate whether testicular organoids might be useful in answering current scientific questions about the regulation and function of the SSC niche as well as germ cell proliferation and differentiation, and whether or not the existing in vitro models are already sufficient to address them. Moreover, we would like to discuss how an organoid system can be a better solution to address these prominent scientific problems in our field, by the creation of a rationale parallel to those in other areas where organoid systems have been successfully utilized. We comprehensively reviewed publications regarding testicular organoids and the methods that most closely led to the formation of these organ-like structures in vitro by searching for the following terms in both PubMed and the Web of Science database: testicular organoid, seminiferous tubule 3D culture, Sertoli cell 3D culture, testicular cord formation in vitro, testicular morphogenesis in vitro, germ cell 3D culture, in vitro spermatogenesis, testicular de novo morphogenesis, seminiferous tubule de novo morphogenesis, seminiferous tubule-like structures, testicular in vitro model and male germ cell niche in vitro, with no restrictions to any publishing year. The inclusion criteria were based on the relation with the main topic (i.e. testicular organoids, testicular- and seminiferous-like structures as in vitro models), methodology applied (i.e. in vitro culture, culture dimensions (2D, 3D), testicular cell suspension or fragments) and outcome of interest (i.e. organization in vitro). Publications about grafting of testicular tissue, germ-cell transplantation and female germ-cell culture were excluded. The application of organoid systems is making its first steps in the field of reproductive medicine and biology. A restricted number of publications have reported and characterized testicular organoids and even fewer have denominated such structures by this method. However, we detected that a clear improvement in testicular cell reorganization is recognized when 3D culture conditions are utilized instead of 2D conditions. Depending on the scientific question, testicular organoids might offer a more appropriate in vitro model to investigate testicular development and physiology because of the easy manipulation of cell suspensions (inclusion or exclusion of a specific cell population), the fast reorganization of these structures and the controlled in vitro conditions, to the same extent as with other organoid strategies reported in other fields. By way of appropriate research questions, we might use testicular organoids to deepen our basic understanding of testicular development and the SSC niche, leading to new methodologies for male infertility treatment.